Paranasal Sinus Squamous Cell Carcinoma
5 clinical trials · Condition
◉ Watch Paranasal Sinus Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma (NCT03381183) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-21 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (NCT03468218) | Emory University | 2018-09-18 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer (NCT01267240) | National Cancer Institute (NCI) | 2010-12-01 |
Track Paranasal Sinus Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.